- Launches 'AI-Totalis 35' to predict 35 major diseases — including kidney disease, cancer, cardiovascular, and pulmonary conditions — using blood tests alone
- U.S. AI organ prediction monitoring royalty revenue and preventive medicine leadership to commence in Q3 2026
- Entering world-first kidney regeneration surgery with skin, cartilage, and high-momentum milestones

ROKIT Healthcare (KOSDAQ: 376900), a specialist in AI-driven hyper-personalized organ regeneration platforms, is disrupting the limitations of conventional disease-treatment-centric medicine. The company has built the world's first 'PPR Integrated AI Medical Platform' — capable of predicting the onset of disease before it occurs, enabling prevention, improving organ function through age-reversal, and ultimately regenerating organs.

This represents a strategic evolution from a regenerative medicine company into a 'hyper-personalized AI prediction, prevention, and regeneration platform company' that can dramatically reduce global healthcare expenditure and transform the global medical market.

Reading the Future of 35 Diseases from Blood… Completing the Ultra-Precision Prediction Platform 'AI-Totalis 35'

ROKIT Healthcare's new core growth engine is 'AI-Totalis 35,' an AI prediction platform trained on 26 years of big data (1998–2024) from approximately 250,000 patients.

'AI-Totalis 35' precisely predicts the risk of developing 35 major diseases using only blood tests and clinical data. In particular, the AI kidney function prediction monitoring system — which can forecast chronic kidney disease up to five years in advance — enables proactive, personalized prevention. This solution is gaining significant attention as a key tool for reducing enormous social costs.

Starting in Q3 2026, royalty revenues from the platform's system integration in the United States are expected to materialize. In addition, AI-Totalis 35's full commercial global launch is anticipated in Q4 2026.

The key disease prediction pipeline of AI-Totalis 35 includes seven major cancers (gastric, colorectal, liver, lung, breast, thyroid, and cervical cancer), as well as chronic and metabolic conditions such as chronic kidney disease (CKD), diabetes, dyslipidemia, and obesity. It also covers 7 cardiovascular and liver diseases, 6 musculoskeletal conditions, and 11 respiratory and other diseases.

When AI-Totalis 35 identifies a risk of disease onset, AI-FRESH intervenes immediately to improve organ function.

AI-FRESH is a solution that goes beyond the limitations of conventional PRP (Platelet-Rich Plasma) therapy. Rather than simply injecting growth factors, it establishes a 'bioactive fibrin-based regenerative microenvironment.' Through this approach, the company is expanding its market reach into orthopedic conditions such as knee osteoarthritis and rotator cuff injuries, as well as aesthetic skin regeneration.

From Treatment to Prediction, Prevention, and Regeneration… Completing the World's First 'PPR Value Chain'

Following ▲AI-Totalis 35 (precision disease prediction) and ▲AI-FRESH (organ function improvement and prevention), ROKIT Healthcare is now entering the world's first human clinical trial for artificial kidney regeneration in Korea. This completes the final piece of the puzzle: ▲AI bioprinting-based organ regeneration (AI hyper-personalized regeneration) — bringing the full PPR ecosystem to life.

A ROKIT Healthcare spokesperson stated: "While the conventional medical industry remained focused on the passive 'symptom relief and mass treatment' approach after disease onset, we concentrated on a preemptive and fundamental solution — hyper-personalized prediction, prevention, and regeneration — driven by a contrarian perspective. Rather than settling for short-term partial solutions, our goal is to build an antifragile, integrated medical business model that can grow explosively regardless of external shocks or market volatility. Through the global expansion of our PPR (Prediction, Prevention & Regeneration) medical platform, we will set a new standard for precision medicine worldwide."